|64.56||-1.34||-2.03%||Vol 141.71K||1Y Perf 30.41%|
|Apr 19th, 2021 13:27 DELAYED|
|- -%||- -|
|Target Price||91.38||Analyst Rating||Strong Buy 1.00|
|Potential %||41.39||Finscreener Ranking||★★★★ 55.07|
|Insiders Trans % 3/6/12 mo.||-100/-76/-89||Value Ranking||★★★★+ 59.80|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★+ 56.38|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||3.90B||Earnings Rating||Sell|
|Price Range Ratio 52W %||43.55||Earnings Date||6th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th May 2021|
|Estimated EPS Next Report||-2.19|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||337.39K|
|Avg. Monthly Volume||423.29K|
|Avg. Quarterly Volume||497.71K|
Arena Pharmaceuticals Inc. (NASDAQ: ARNA) stock closed at 65.9 per share at the end of the most recent trading day (a -3.07% change compared to the prior day closing price) with a volume of 684.16K shares and market capitalization of 3.90B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 363 people. Arena Pharmaceuticals Inc. CEO is Amit D. Munshi.
The one-year performance of Arena Pharmaceuticals Inc. stock is 30.41%, while year-to-date (YTD) performance is -14.23%. ARNA stock has a five-year performance of 256.22%. Its 52-week range is between 44.79 and 90.19, which gives ARNA stock a 52-week price range ratio of 43.55%
Arena Pharmaceuticals Inc. currently has a PE ratio of -9.00, a price-to-book (PB) ratio of 3.71, a price-to-sale (PS) ratio of 68 548.60, a price to cashflow ratio of 4.50, a PEG ratio of 2.32, a ROA of -32.78%, a ROC of -30.74% and a ROE of -36.02%. The company’s profit margin is 47.34%, its EBITDA margin is -124 249.00%, and its revenue ttm is $57.00 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from Arena Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-2.19 for the next earnings report. Arena Pharmaceuticals Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Arena Pharmaceuticals Inc. is Strong Buy (1), with a target price of $91.38, which is +41.39% compared to the current price. The earnings rating for Arena Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Arena Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Arena Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.15, ATR14 : 3.59, CCI20 : -64.14, Chaikin Money Flow : -0.18, MACD : -3.26, Money Flow Index : 34.79, ROC : -1.96, RSI : 45.52, STOCH (14,3) : 21.42, STOCH RSI : 0.69, UO : 32.28, Williams %R : -78.58), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Arena Pharmaceuticals Inc. in the last 12-months were: Amit D. Munshi (Option Excercise at a value of $5 835 755), Amit D. Munshi (Sold 406 194 shares of value $28 047 382 ), Christopher Cabell (Option Excercise at a value of $341 640), Christopher Cabell (Sold 13 000 shares of value $884 000 ), Jayson Dallas (Buy at a value of $678), Jayson Dallas (Sold 1 327 shares of value $106 824 ), Manmeet Singh Soni (Sold 3 262 shares of value $197 704 ), Nova Susan Tina (Option Excercise at a value of $627 200), Nova Susan Tina (Sold 34 600 shares of value $2 350 606 ), Robert Lisicki (Option Excercise at a value of $1 945 125), Robert Lisicki (Sold 51 372 shares of value $3 536 439 ), Vincent Aurentz (Option Excercise at a value of $386 354), Vincent Aurentz (Sold 27 524 shares of value $1 839 562 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.